April 14th 2025
Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Oxford Genetics and University of Oxford Form Virus Production Pact
November 23rd 2016Oxford Genetics has been awarded a grant to develop packaging cell lines for virus bioproduction and will work in collaboration with the University of Oxford to generate cell lines for the scalable manufacture of retrovirus and lentivirus vectors.